A clinical genetics approach to stroke in children and young adults — covering monogenic stroke syndromes, CADASIL, mitochondrial stroke-like episodes, hereditary coagulopathies, and the role of genetic testing in guiding diagnosis and secondary prevention.
Tags: Neurogenetics · Advanced
Approximately 5–10% of all strokes and up to 25–30% of strokes in patients under 45 years have a definable genetic cause. Genetic stroke syndromes should be suspected when stroke occurs in young patients, is recurrent, affects multiple family members, is associated with specific non-stroke neurological features, or has characteristic MRI findings. A systematic approach to genetic diagnosis has direct therapeutic implications and informs family member screening.
Key Points
CADASIL is the most common hereditary stroke disorder in adults, caused by autosomal dominant pathogenic variants in NOTCH3 — specifically stereotyped cysteine-altering variants in the epidermal growth factor-like repeat (EGF-r) domain of the extracellular domain, causing protein aggregation in the walls of small arteries throughout the body. It is a primary arteriopathy — not a coagulopathy — affecting cerebral small vessels.
Key Points
Stroke-like episodes (SLEs) in MELAS differ fundamentally from ischemic stroke: they are caused by focal neuronal energy failure, not vascular occlusion. This distinction has critical management implications — thrombolytics are contraindicated. MELAS is most commonly caused by the m.3243A>G variant in MT-TL1 with maternal inheritance and variable heteroplasmy. For comprehensive coverage of MELAS and mitochondrial disorders, see the Mitochondrial Disorders module.
Key Points
Several hereditary conditions affecting coagulation or vascular wall structure predispose to ischemic stroke or intracranial hemorrhage. These conditions require specific genetic testing and targeted management distinct from the general approach to stroke secondary prevention.
Key Points
A systematic, stepwise approach to genetic evaluation in young stroke patients maximizes diagnostic yield while remaining cost-effective. The workup is guided by clinical phenotype, stroke mechanism (ischemic vs. hemorrhagic, large vessel vs. small vessel vs. cardioembolic), and family history. Genetic diagnosis has implications for treatment, secondary prevention, and family screening.
Key Points
1. A 42-year-old woman with a 15-year history of migraine with aura presents with acute confusion and left-sided weakness. MRI shows a new right-sided lacunar infarct, extensive periventricular white matter hyperintensities, and prominent signal changes in the anterior temporal lobes bilaterally. Her 70-year-old mother has vascular dementia. NOTCH3 sequencing reveals a cysteine-altering variant in exon 4 (EGF-r domain). Her neurologist considers starting anticoagulation for secondary stroke prevention. Is this appropriate?
CADASIL is a primary arteriopathy, not a thromboembolic disorder. Anticoagulation has not been shown to reduce recurrent stroke risk in CADASIL and may increase the risk of intracerebral hemorrhage — a known complication of advanced CADASIL. Current management recommendations include antiplatelet therapy (typically aspirin), aggressive blood pressure control, statin therapy, and management of other vascular risk factors. Migraine management should avoid triptans in patients with active infarct history. Understanding that CADASIL strokes result from arteriopathic small vessel disease rather than thromboembolism is essential for appropriate secondary prevention.
2. A 20-year-old woman presents with seizures and a right homonymous hemianopia. MRI shows cortical restricted diffusion in the left parieto-occipital region that does NOT respect vascular territory boundaries. She has short stature, bilateral sensorineural hearing loss, and diabetes diagnosed at age 16. Her serum lactate is elevated. Her mother has similar hearing loss and diabetes. Which medication must be AVOIDED in this patient?
This patient has classic features of MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes): young age, stroke-like episode crossing vascular territories, seizures, short stature, hearing loss, diabetes, elevated lactate, and maternal inheritance pattern. Valproic acid is contraindicated in mitochondrial disorders because it inhibits complex I of the electron transport chain and impairs mitochondrial fatty acid beta-oxidation, potentially triggering metabolic crisis and liver failure. Safe anticonvulsant alternatives include levetiracetam and lacosamide. Additionally, metformin should be avoided for her diabetes because it inhibits complex I and can worsen lactic acidosis. Acute management of the stroke-like episode includes IV L-arginine (a nitric oxide precursor) and seizure control.
3. A 28-year-old woman with no cardiovascular risk factors presents with cerebral venous sinus thrombosis. She is on combined oral contraceptive pills and recently took a long-haul flight. Thrombophilia testing reveals heterozygous Factor V Leiden. Which statement about her ongoing stroke risk management is MOST accurate?
Heterozygous Factor V Leiden (c.1601G>A, p.Arg506Gln) is the most common inherited thrombophilia (~5% of Europeans) and confers a 3-7 fold increased risk of venous thromboembolism (VTE). However, most heterozygous carriers never develop thrombosis unless additional risk factors are present — oral contraceptives (which increase VTE risk 3-4 fold independently) create a multiplicative risk when combined with Factor V Leiden. The most important intervention is discontinuing estrogen-containing contraceptives and switching to a progestin-only or non-hormonal method. Lifelong anticoagulation is generally not indicated for heterozygous carriers after a first provoked event, though duration of anticoagulation after the acute event should be individualized. Factor V Leiden predominantly affects the venous system; its association with arterial stroke is modest.
4. A 35-year-old woman with known CADASIL (confirmed NOTCH3 cysteine-altering variant) and two prior lacunar strokes develops a severe migraine with prolonged aura. Her neurologist previously prescribed sumatriptan (a triptan) for migraine relief. Is this medication appropriate for her?
Triptans (5-HT1B/1D receptor agonists) cause vasoconstriction and are generally contraindicated in patients with cerebrovascular disease. In CADASIL patients who have already experienced ischemic events, the vasoconstrictive properties of triptans could theoretically worsen cerebral ischemia in the setting of already compromised small vessels. Migraine management in CADASIL should rely on preventive medications (e.g., verapamil, amitriptyline) and non-vasoconstrictive acute treatments. This is an important practical consideration because migraine with aura is often the earliest symptom of CADASIL, appearing in the third to fourth decade — before ischemic strokes begin.
5. A 25-year-old man with corneal verticillata (corneal opacity), chronic burning pain in his hands and feet since childhood, clustered angiokeratomas on his trunk, and proteinuria presents with an acute ischemic stroke. His maternal grandmother died of renal failure at age 50. An enzyme assay shows markedly reduced alpha-galactosidase A activity. Which statement about his ongoing management is CORRECT?
This patient has Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (GLA gene). The deficiency leads to accumulation of globotrianosylceramide (Gb3) in vascular endothelium, neurons, cardiac tissue, and kidneys. Stroke in the third to fourth decade, acroparesthesias, angiokeratomas, corneal verticillata, and progressive renal disease are the classic features. The maternal family history (affected maternal grandmother with renal failure) fits the X-linked inheritance pattern. Enzyme replacement therapy with recombinant agalsidase alfa or beta is available and reduces Gb3 accumulation, slowing disease progression. This is one of the most clinically important examples where identifying the genetic cause of stroke directly changes management beyond standard secondary prevention.